EMEIS : No turn-around in sight
Entry price | Target | Stop-loss | Potential |
---|
€94.6 |
€106 |
€90.5 |
+12.05% |
---|
Shares in Orpea show a positive technical chart pattern over the medium term. The timing to jump back on the rising trend seems good.
Summary● The company has solid fundamentals for a short-term investment strategy.
Strengths● There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
● Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
● Over the last twelve months, the sales forecast has been frequently revised upwards.
● Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
● The stock is in a well-established, long-term rising trend above the technical support level at 79.91 EUR
Weaknesses● Stock prices approach a strong long-term resistance in weekly data at EUR 100.34.
● One of the major weak points of the company is its financial situation.
● With a 2017 P/E ratio at 27.4 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.